| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S2213-8587(18)30154-2 |
| P698 | PubMed publication ID | 30174213 |
| P50 | author | Hans-Ulrich Häring | Q63256451 |
| P2093 | author name string | Norbert Stefan | |
| Kenneth Cusi | |||
| P2860 | cites work | Insulin signalling and the regulation of glucose and lipid metabolism | Q24292020 |
| Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis | Q24625697 | ||
| Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions | Q26751258 | ||
| The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis | Q26777980 | ||
| Mechanisms and metabolic implications of regional differences among fat depots | Q27004113 | ||
| Genetics and epigenetics of NAFLD and NASH: Clinical impact | Q47623021 | ||
| Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes | Q47683156 | ||
| Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial | Q47691659 | ||
| Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. | Q47765250 | ||
| Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum | Q47771118 | ||
| Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases | Q47779219 | ||
| Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. | Q47785505 | ||
| Use of Liver Imaging and Biopsy in Clinical Practice | Q47790032 | ||
| Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study | Q47956183 | ||
| Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. | Q48086288 | ||
| Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. | Q48146370 | ||
| Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease | Q49647333 | ||
| Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis | Q49797701 | ||
| Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option | Q50055776 | ||
| Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? | Q50132292 | ||
| Noninvasive Assessment of Liver Fibrosis. | Q50996360 | ||
| Pioglitazone for diabetes prevention in impaired glucose tolerance. | Q51161029 | ||
| TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. | Q51271856 | ||
| Serum markers detect the presence of liver fibrosis: a cohort study. | Q51983072 | ||
| A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. | Q52644811 | ||
| Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. | Q53307617 | ||
| Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. | Q55386487 | ||
| EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease | Q60462090 | ||
| Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis | Q60462195 | ||
| The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD | Q61989968 | ||
| Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial) | Q86416747 | ||
| Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease | Q27496667 | ||
| Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial | Q28253122 | ||
| Nonalcoholic fatty liver disease: a systematic review | Q28263139 | ||
| Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease | Q29619334 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action | Q30235619 | ||
| Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis | Q30238749 | ||
| Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening | Q30277347 | ||
| Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease | Q30445138 | ||
| Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis | Q30592294 | ||
| Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records | Q31095975 | ||
| The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population | Q33262505 | ||
| Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis | Q33563333 | ||
| Geroscience: linking aging to chronic disease | Q34449096 | ||
| Lipoprotein subclass metabolism in nonalcoholic steatohepatitis | Q34565315 | ||
| Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
| A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis | Q34585893 | ||
| Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. | Q34671802 | ||
| Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Identification and characterization of metabolically benign obesity in humans | Q34807153 | ||
| Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease | Q34812618 | ||
| Metabolically normal obese people are protected from adverse effects following weight gain | Q35056761 | ||
| The sexual dimorphism of obesity | Q35077539 | ||
| Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease | Q35893923 | ||
| Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis | Q36236746 | ||
| Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis | Q36291761 | ||
| Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice | Q36828380 | ||
| Pioglitazone after Ischemic Stroke or Transient Ischemic Attack | Q36953272 | ||
| Causes and metabolic consequences of Fatty liver | Q37250791 | ||
| Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity | Q37340863 | ||
| Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins | Q37411799 | ||
| The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation | Q42735428 | ||
| The impact of liver fat vs visceral fat in determining categories of prediabetes | Q43184911 | ||
| Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention | Q45067817 | ||
| Exome-wide association study of plasma lipids in >300,000 individuals | Q45071322 | ||
| Endoplasmic reticulum stress induces hepatic steatosis via increased expression of the hepatic very low-density lipoprotein receptor | Q45200756 | ||
| Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). | Q46012959 | ||
| Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. | Q46124754 | ||
| Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis | Q46418008 | ||
| Preclinical models of non-alcoholic fatty liver disease | Q46474258 | ||
| Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions | Q46476704 | ||
| Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. | Q46548459 | ||
| Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans | Q47196570 | ||
| Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals | Q47307583 | ||
| A critical review of endpoints for non-cirrhotic NASH therapeutic trials | Q47338078 | ||
| Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis | Q47394340 | ||
| Lipotoxicity and the gut-liver axis in NASH pathogenesis. | Q47444988 | ||
| An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis | Q47583526 | ||
| Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study | Q37657417 | ||
| Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease | Q37682697 | ||
| Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis | Q37744428 | ||
| Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. | Q37976341 | ||
| Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications | Q37983300 | ||
| Nonalcoholic fatty liver disease: current issues and novel treatment approaches | Q38074898 | ||
| The role of hepatokines in metabolism | Q38075770 | ||
| The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. | Q38102596 | ||
| Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome | Q38204542 | ||
| Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies | Q38207382 | ||
| NAFLD: a multisystem disease. | Q38446387 | ||
| Review article: new treatments in non-alcoholic fatty liver disease. | Q38662765 | ||
| Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice | Q38668329 | ||
| The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. | Q38676257 | ||
| Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. | Q38680300 | ||
| Divergent associations of height with cardiometabolic disease and cancer: epidemiology, pathophysiology, and global implications | Q38716864 | ||
| Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease | Q38731798 | ||
| Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance | Q38760082 | ||
| Phenotypes of prediabetes and stratification of cardiometabolic risk | Q38835951 | ||
| Pharmacological management of nonalcoholic fatty liver disease | Q38853183 | ||
| Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. | Q38897034 | ||
| Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States | Q38924700 | ||
| Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis | Q38972188 | ||
| NAFLD and diabetes mellitus | Q38978347 | ||
| Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus | Q39002475 | ||
| An extended fatty liver index to predict non-alcoholic fatty liver disease | Q39019673 | ||
| Renal, metabolic and cardiovascular considerations of SGLT2 inhibition | Q39035951 | ||
| Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population | Q39693472 | ||
| A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis. | Q40082820 | ||
| Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. | Q40084558 | ||
| Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. | Q40402519 | ||
| Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. | Q40422340 | ||
| Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease | Q40444861 | ||
| Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. | Q41482573 | ||
| Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease | Q41583750 | ||
| Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. | Q41689452 | ||
| Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. | Q41689462 | ||
| Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management | Q41725283 | ||
| Metabolically healthy obesity: the low-hanging fruit in obesity treatment? | Q41997280 | ||
| Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study | Q42176482 | ||
| Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up | Q42201783 | ||
| Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci | Q42347122 | ||
| P433 | issue | 4 | |
| P921 | main subject | liver disease | Q929737 |
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| non-alcoholic fatty liver | Q66299798 | ||
| P304 | page(s) | 313-324 | |
| P577 | publication date | 2018-08-30 | |
| P1433 | published in | The Lancet: Diabetes & Endocrinology | Q27725107 |
| P1476 | title | Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies | |
| P478 | volume | 7 |
| Q64064053 | Association between ADIPOQ G276T and C11377G polymorphisms and the risk of non-alcoholic fatty liver disease: An updated meta-analysis |
| Q92200921 | Association between red cell distribution width-to-platelet ratio and hepatic fibrosis in nonalcoholic fatty liver disease: A cross-sectional study |
| Q96591266 | Causes, consequences, and treatment of metabolically unhealthy fat distribution |
| Q92537609 | Children With Metabolically Healthy Obesity: A Review |
| Q92826678 | Dietary Fructose and the Metabolic Syndrome |
| Q64939339 | Effect of sodium-glucose cotransporter type 2 inhibitors on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection? |
| Q92003593 | Effects of XIAP on high fat diet-induced hepatic steatosis: a mechanism involving NLRP3 inflammasome and oxidative stress |
| Q92946356 | Fatty liver and mortality: a cohort population study in South Italy |
| Q64252579 | Glucagon-Induced Acetylation of Energy-Sensing Factors in Control of Hepatic Metabolism |
| Q90583682 | Hepatic steatosis in patients with acromegaly |
| Q90047443 | Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis |
| Q92415839 | Hepatocyte-specific Nrf2 deficiency mitigates high-fat diet-induced hepatic steatosis: Involvement of reduced PPARγ expression |
| Q64067048 | Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease |
| Q64057672 | Implications of altered NAD metabolism in metabolic disorders |
| Q93015261 | Insulin resistance associates with hepatic lobular inflammation in subjects with obesity |
| Q101461111 | Loss of Hepatic Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Links Nonalcoholic Steatohepatitis to Atherosclerosis |
| Q91605715 | Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: a pooled analysis of the diagnostic accuracy |
| Q97543628 | NAFLD in type 2 diabetes mellitus - still many challenging questions |
| Q94479096 | Non-alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance |
| Q90248138 | Non-invasive Quantification of Fat Deposits in Skeletal Muscle Predicts Cardiovascular Outcome in Kidney Failure |
| Q64113047 | Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment |
| Q90671739 | PGC-1α, Inflammation, and Oxidative Stress: An Integrative View in Metabolism |
| Q92543106 | PNPLA3-A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease |
| Q92049144 | Paraoxonase-1 Serum Concentration and PON1 Gene Polymorphisms: Relationship with Non-Alcoholic Fatty Liver Disease |
| Q92714849 | Predictive value and clinical significance of increased SSAT-1 activity in healthy adults |
| Q98185257 | Prenatal Exposure to Perfluoroalkyl Substances Associated with Increased Susceptibility to Liver Injury in Children |
| Q64113073 | Progressive reduction in skeletal muscle mass to visceral fat area ratio is associated with a worsening of the hepatic conditions of non-alcoholic fatty liver disease |
| Q91861797 | [Exendin-4 alleviates oxidative stress and liver fibrosis by activating Nrf2/HO-1 in streptozotocin-induced diabetic mice] |
Search more.